Wagner Wealth Management (South Carolina)’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-100
Closed -$29K – 682
2022
Q3
$29K Sell
100
-134
-57% -$38.6K 0.02% 261
2022
Q2
$66K Buy
+234
New +$62.6K 0.05% 177
2022
Q1
– Sell
-100
Closed -$22K – 644
2021
Q4
$22K Hold
100
– – 0.02% 388
2021
Q3
$18K Hold
100
– – 0.01% 393
2021
Q2
$20K Hold
100
– – 0.01% 386
2021
Q1
$21K Buy
+100
New +$22K 0.02% 359
2018
Q3
$19K Hold
100
– – 0.01% 354
2018
Q2
$17K Buy
100
+35
+54% +$5.42K 0.01% 334
2018
Q1
$11K Buy
65
+9
+16% +$1.47K 0.01% 361
2017
Q4
$9K Buy
+56
New +$8.29K 0.01% 427

Other funds holding VRTX

Wagner Wealth Management (South Carolina)'s VRTX Position: Q4 2022 in Review

Wagner Wealth Management (South Carolina) sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 100 shares — an estimated $29K sold.

Wagner Wealth Management (South Carolina) first reported a position in VRTX in Q4 2017 and held it in 10 quarters. The position peaked at $66K in Q2 2022. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • Wagner Wealth Management (South Carolina) reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Wagner Wealth Management (South Carolina) sold 100 Vertex Pharmaceuticals shares in Q4 2022, an estimated $29K.
  • Wagner Wealth Management (South Carolina) first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 10 quarters.
  • Wagner Wealth Management (South Carolina)'s Vertex Pharmaceuticals position peaked at $66K in Q2 2022.
  • 1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Wagner Wealth Management (South Carolina)'s 13F filing for Q4 2022, filed 14 Feb 2023.